FARE Clinical Trial Finder

Simplify your search for a clinical trial and help researchers discover new therapies. The FARE Clinical Trial Finder links patients with food allergy and healthy, non-patient volunteers to actively recruiting food allergy studies.

Step Down Approach in Children With Cow Milk Allergy

Study Purpose

Cow's milk allergy (CMA) affects up to 3% of European children. In the absence of an alternative to cow's milk, the management of CMA is based on the use of safe, affordable and nutritionally adequate formulas. In Scientific Societies Guidelines, extensively hydrolyzed casein formula (EHCF) is considered as safe first line approach for the treatment of children with CMA, whereas amino acid-based formula (AAF) is considered as second line strategy in children reacting to EHCF or as first line approach in children with CMA-induced anaphylaxis. Few and not recent studies, involving a poorly characterized study population, suggested that up to 10% of CMA children could react to the extensively hydrolysed formulas. It has been demonstrated that EHCF supplemented with L.rhamnosus GG (LGG) maintains hypoallergenic status and that is able to accelerate oral tolerance acquisition in children with CMA comparing with other formulas. The purpose of this study is to investigate the feasibility of a "step-down" approach in children affected by Immunoglobulin E (IgE)-mediated CMA with the aim to evaluate the effects of EHCF + LGG on oral tolerance acquisition and on immune response and gut microbiota shaping.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages N/A - 6 Months
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Infants aged <6 months - sure diagnosis of IgE-mediated CMA confirmed by positive oral food challenge for cow's milk and or blood Cow milk protein specific IgE>0.1kiloUnits/Liter and/or Skin Prick Testing (SPT) for milk wheal size ≥ 3mm - children receiving AAF for at least 4 weeks - full and stable remission of CMA symptoms.

Exclusion Criteria:

  • - Infant aged > 6 months, - CMP-induced anaphylaxis, - evidence of non-IgE-mediated CMA, - other food allergies, - other allergic diseases, - eosinophilic disorders of the gastrointestinal tract, - chronic systemic diseases, - congenital cardiac defects, - active tuberculosis, - autoimmune diseases, - immunodeficiency, - chronic inflammatory bowel diseases, - celiac disease, - cystic fibrosis, - metabolic diseases, - malignancy, - chronic pulmonary diseases, - malformations of the gastrointestinal and/or respiratory tract, - administration of prebiotics or probiotics during the 4 weeks before enrolment, - use of systemic antibiotics or anti-mycotic drugs during 4 weeks before study entry; - investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements; - participation in any other studies involving investigational or marketed products concomitantly or within two weeks prior to entry into the study.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03449537
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Federico II University
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Not yet recruiting
Countries
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Allergy Milk
Additional Details

60 Immunoglobulin E-mediated CMA children, consecutively observed at tertiary Centers for Food Allergy, who will meet the inclusion criteria will be invited to participate to the study. Anamnestic, demographic, anthropometric and clinical data, as well as information on socio-demographic factors, family and living conditions, parental history of allergic diseases, number of siblings, and pet ownership will be obtained from the parents of each infant and recorded in a clinical database. Then in all subjects an oral food challenge with EHCF + LGG will be performed. Only subjects with negative oral food challenge will be randomly allocated to one of the two groups of dietary interventions for a 12 months follow up period: group 1 received AAF , and group 2 received EHCF + LGG. Effective use of the formula will be evaluated during the study by dieticians counselling parents about issues that could arise during the elimination diet. Parents or caregivers will be asked to keep a daily record of formula use. The amount prepared (millimetres of water and number of formula spoons) and amount left after each consumption will be recorded in a diary to assess the amount consumed by the child. At enrolment, after 6 and 12 months body growth will be assessed by body weight, body length and head circumference measured at enrolment, after 6 and 12 months of follow-up with reference to growth charts. Unscheduled visits will be made if necessary. In addition at enrolment, after 6 and 12 months, the investigators will perform: 1. All Oral food challenge procedures will be performed in double blind fashion in 2 consecutive days. Full emergency equipment and drugs (epinephrine, antihistamines, steroids) will be at hand. The challenge will be stopped upon the appearance of clinical symptoms or when the highest dose will be reached. The child will be observed for 2 h, and then discharged. 2. Skin prick test (whole milk, casein, α-lactalbumin, β-lactoglobulin): allergens and fresh milk will be applied to the patients volar forearm: cow's milk (CM) containing 3.5% fat. Skin prick tests were performed using a 1-mm single peak lancet (ALK, Copenhagen, Denmark), with histamine dihydrochloride (10 mg/ml) and isotonic saline solution (NaCl 0.9%) as positive and negative control, respectively. Reactions will be recorded on the basis of the largest diameter (in millimetres) of the wheal and flare at 15 min. The SPT result will be considered "positive" if the wheal was 3 mm or larger, without reaction of the negative control. 3. Total IgE and specific IgE and Immunoglobulin G 4 against proteins and epitopes of cow's milk: we will perform a venous blood sample; serum of the patients will be collected using tube serum separator tubes and was obtained by centrifugation for 10-15 minutes. Serum will be flash frozen and stored at −80 °C until further analysis. From serum, total IgE and specific IgE and IgG4 against proteins and epitopes of cow's milk will be analyzed with enzymatic immunoassay. 4. Gut microbiota composition: a stool sample will be collect and immediately frozen to −80°C and stored until further analysis. Total genomic DNA (gDNA) will be isolated from fecal material using a specific DNA. Isolation kit and gut microbiota composition will be analysed using an approach for bacteria and an internal transcribed spacer region sequencing approach (High-throughput sequencing). 5. Short chain fatty acids (SCFAs) fecal and serum production: a stool sample and serum will be collect. One gram of fecal samples will be weighed, diluted 1:2 in sterile phosphate-buffered saline solution, and homogenized. Supernatants will be then obtained by centrifugation (10 000g, 30 minutes, 4°C), filtered through 0.2-μm filters and stored at −80°C until analysis. Serum of the patients will be collected using tube serum separator tubes and was obtained by centrifugation for 10-15 minutes. Serum will be flash frozen and stored at −80 °C until further analysis. Analysis of SCFAs will be performed using gas chromatography-mass spectrometry (MS) to measure the concentrations of acetic, propionic, and butyric acid in fecal samples. 6. Serum level of interleukin (IL)-4, IL-5, IL-13, IL-10, interferon (IFN)-γ: we will perform a venous blood sample; serum of the patients will be collected using tube serum separator tubes and was obtained by centrifugation for 10-15 minutes. Serum will be flash frozen and stored at −80 °C. From serum, IL-4, IL-5, IL-13, IL-10, IFN-γ will be determined by ELISA (specific kit for each cytokine). 7. Methylation status of the promoter region of genes involved in IgE-mediated allergy, IL-4, IL-5, IL-13, IL-10 and IFN-γ and of FoxP3+: Venous blood will be obtained from the patients and DNA will be extracted from leukocytes using DNA Extraction Kit. Extracted DNA will be modified with sodium bisulfite using the Methylation Gold Kit (ZYMO Research Co.) according to the manufacturer's instructions. The converted DNA will be stored at −70°C until used. Methylation analyses will be performed using High resolution melting Real Time (LightCycler® 480, Roche Applied Science). The results will be confirmed by direct sequencing (Sanger method modified: ddNTPs labeled with four different fluorophores).

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

For additional contact information, you can also visit the trial on clinicaltrials.gov.

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.